Clinical Trial News and Research

RSS

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.

23 Nov 2009

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical Corp. today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco.

23 Nov 2009

Initiation of Phase I/IIa clinical trial of IL-7 announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa clinical trial of IL-7 in support of tumor lysate/KLH pulsed dendritic cell vaccines in a pilot study of tumor vaccination in patients with metastatic or recurrent pediatric solid tumors and altered T cell homeostasis, including patients with Ewing’s sarcoma family of tumors (ESFT), rhabdomyosarcoma, neuroblastoma, synovial cell sarcoma, desmoplastic small round cell tumor, undifferentiated sarcoma, and embryonal sarcoma.

23 Nov 2009

Genes from same 'family' interact with each other to prevent skin cancer, says new study

CANCER RESEARCH UK scientists have shown, for the first time, how two genes from the same 'family' can interact with each other to stop cancer in its tracks - according to new findings published in Molecular Cell.

23 Nov 2009

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.

22 Nov 2009

Review of study presented at American Heart Association Scientific Sessions

Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8 months, with further improvement seen at the end of the study (14 months).

21 Nov 2009

Positive results from recently completed phase II clinical study of ToleroMune therapy announced

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development.

20 Nov 2009

Pediatric immunologist receives prestigious annual award from American Philosophical Society

A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize on Nov. 13 for his contributions to research and treatment of inherited immune deficiency diseases.

20 Nov 2009

Advocacy groups team up to offer personalized education about clinical trials for lung cancer patients

Leading patient advocacy organizations announced today that they are teaming up for the first time on an initiative to encourage patients with lung cancer to take charge of their diagnosis and learn about clinical trials, which are an important part of treatment innovation.

20 Nov 2009

2009 Report Card, an overall assessment of efforts to reduce lung cancer's mortality released

Today, Lung Cancer Alliance (LCA) released its annual National Report Card on Lung Cancer, an overall assessment of efforts to reduce lung cancer's mortality.

20 Nov 2009

Curemark begins enrolling patients in Phase III clinical trials for CM-AT

Curemark LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has begun enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at three additional clinical trial sites.

20 Nov 2009

MONITORING FORCE files for Flibanserin orphan drug status designation with the EMEA

MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and preventing them from receiving optimal treatment for Parkinson's.

19 Nov 2009

Advanced Cell Technology files an IND with the FDA for study using embryonic stem cells to treat SMD

Advanced Cell Technology, Inc. announced today that it filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Among the most common causes of untreatable blindness in the world are degenerative diseases of the retina.

19 Nov 2009

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.

19 Nov 2009

Cardiovascular Systems commences patient enrollment in CALCIUM 360° clinical trial

Cardiovascular Systems, Inc., announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company’s 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI’s Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg.

19 Nov 2009

Recent progress of Delcath Systems in drug delivery platform reported

Delcath Systems, Inc., a medical technology company developing the Delcath Percutaneous Hepatic Perfusion (PHP(TM)) System, a minimally invasive drug delivery platform for the regional treatment of cancer metastatic to the liver, today reported on the Company's recent progress.

19 Nov 2009

Treatment of iron deficiency can improve symptoms and quality of life in CHF patients

Intravenous (I.V.) iron treatment with ferric carboxymaltose to reverse iron deficiency can significantly improve symptoms, exercise tolerance and quality of life for chronic heart failure (CHF) patients, researchers said in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

Continuous flow heart pump improves survival rates in heart failure patients than current pulsating models

A new, continuous flow heart pump, or left ventricular assist device (LVAD), delivered better two-year survival in advanced heart failure patients than the current pulsatile model, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

PanGenex expands clinical trial sites of its Calci-CLEAR system

PanGenex Corporation announced that due to promising pre-clinical results from its clinical trial at the Cardiovascular Institute of the South (http://www.cardio.com/site1.php), the Company will extend its trial to two additional sites.

19 Nov 2009

Clinical Trial News and Research

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical announces results of NGX426 clinical trial

Initiation of Phase I/IIa clinical trial of IL-7 announced

Genes from same 'family' interact with each other to prevent skin cancer, says new study

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Review of study presented at American Heart Association Scientific Sessions

Positive results from recently completed phase II clinical study of ToleroMune therapy announced

Pediatric immunologist receives prestigious annual award from American Philosophical Society

Advocacy groups team up to offer personalized education about clinical trials for lung cancer patients

2009 Report Card, an overall assessment of efforts to reduce lung cancer's mortality released

Curemark begins enrolling patients in Phase III clinical trials for CM-AT

MONITORING FORCE files for Flibanserin orphan drug status designation with the EMEA

Advanced Cell Technology files an IND with the FDA for study using embryonic stem cells to treat SMD

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Cardiovascular Systems commences patient enrollment in CALCIUM 360° clinical trial

Recent progress of Delcath Systems in drug delivery platform reported

Treatment of iron deficiency can improve symptoms and quality of life in CHF patients

Continuous flow heart pump improves survival rates in heart failure patients than current pulsating models

PanGenex expands clinical trial sites of its Calci-CLEAR system

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News